Live
Endpoints NewsADC biotech Ona Therapeutics secures $86.6M in Series B raiseBioPharma DiveA Spanish biotech banks $87M to make differentiated ADCsLonza NewsLonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation - Manufacturing ChemistIlluminaIs Illumina (ILMN) Quietly Solidifying an End‑to‑End Oncology Moat With Deeper DRAGEN Integration? - simplywall.stClinical OMICsCAR T-Cell Therapy Expands Access to Kidney TransplantsEndpoints NewsAlnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealFierceBiotechLilly, Boehringer to slash at least $1B each from planned investments in GermanyClinical OMICsGenetically Raised Pulse Pressure Predisposes to Dementia-Linked DeathClinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 DiabetesFierceBiotechUnlocking Unstructured Data with AI for Optimized Protocol DevelopmentAgilentAgilent partners with OpenAI and BCG to embed AI across scientific instruments and operations - The Business JournalsEndpoints NewsBristol Myers turns focus to AI costs after broad rollout to workers
Endpoints News Feb 28, 2026

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Original
Body unavailable. Use the original source.